Latest Commercialization News

Page 268 of 497
The Takeovers Panel has declined to intervene in PointsBet’s issuance of over 10 million new shares during a fierce takeover contest, affirming the board’s discretion amid competing bids from betr and MIXI Australia.
Claire Turing
Claire Turing
29 Aug 2025
WestStar Industrial reports a 36% revenue decline and a $3.4 million net loss in FY25, driven by reduced activity at SIMPEC. New contract wins post-year-end signal a potential turnaround for FY26.
Victor Sage
Victor Sage
29 Aug 2025
Wide Open Agriculture Limited has trimmed its annual loss to $7.09 million while expanding its lupin protein sales pipeline across key international markets and optimizing production in Germany.
Ada Torres
Ada Torres
29 Aug 2025
Unith Ltd reported a 19% revenue increase to $5.37 million for FY25, driven by its new Digital Human platform launch and B2C expansion, yet net losses widened significantly to $4.95 million. The company’s strategic partnerships and capital raise underpin its growth ambitions amid ongoing cash burn.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Dataworks Group Limited reported a modest revenue increase and a reduced net loss for FY25, underpinned by major contract wins in Canada and Australia. The company is targeting cashflow positivity in the first half of FY26 following operational efficiencies and capital raises.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.
Victor Sage
Victor Sage
29 Aug 2025
Elanor Investors Group reported a substantial $157.8 million net loss for FY24 amid asset devaluations and debt covenant breaches, prompting a strategic recapitalisation and leadership transition.
Eva Park
Eva Park
29 Aug 2025
ASF Group Limited reports a dramatic turnaround to a $25.8 million profit for FY2025, driven by a one-off $32.7 million gain from subsidiary disposals amid a 70% revenue drop.
Victor Sage
Victor Sage
29 Aug 2025
Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.
Ada Torres
Ada Torres
29 Aug 2025
Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.
Ada Torres
Ada Torres
29 Aug 2025
1414 Degrees Ltd reported a widened net loss of $3.34 million for FY25 while advancing its thermal energy storage and hydrogen reactor technologies, supported by fresh equity and government grants.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.
Ada Torres
Ada Torres
29 Aug 2025